Immix Biopharma Formalizes $125M Underwritten Offering with J.P. Morgan, Netting $117.1M
IMMX has more than doubled off its 52-week low of $1.995.
Summary
Immix Biopharma finalized its $125 million underwritten offering with J.P. Morgan, netting approximately $117.1 million to fund NXC-201 development, with participation from leading biotech institutional investors.
Updates
· GlobeNewswire — The offering closed, with net proceeds of approximately $117.1 million.
- J.P. Morgan acted as the sole book-running manager for the offering.
- The offering included participation from leading U.S. biotechnology institutional investors and mutual funds.
Key Events · Financing and Capital Events · IMMX
-
Underwriting Agreement Executed
Immix Biopharma entered into an underwriting agreement with J.P. Morgan Securities LLC to sell 11,363,637 shares at $11.00 per share, with gross proceeds of $125 million.
-
Net Proceeds of $117.1M
After underwriting discounts and estimated offering expenses, the company expects approximately $117.1 million in net proceeds to fund NXC-201 development, working capital, and general corporate purposes.
-
Institutional Investor Participation
The offering included participation from Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments L.P., Wellington Management, and other leading U.S. biotechnology institutional investors.
-
Closing Expected September 30
The offering is expected to close on September 30, 2026, subject to customary closing conditions, with shares listed on the Nasdaq Capital Market.
Analysis · IMMX · Life Sciences
The underwriting agreement with J.P. Morgan for 11.36 million shares at $11.00 per share is now executed, and Immix Biopharma expects approximately $117.1 million in net proceeds to fund NXC-201 development. The offering, which closes September 30, 2026, drew participation from marquee biotech investors including Eventide, Janus Henderson, Ridgeback Capital, and Wellington Management — institutional validation for the company's lead CAR-T program following the 89% complete response rate reported the same day. The 90-day lock-up on officers and directors signals confidence in near-term stability.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.8% of the 1640 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMX was trading at $10.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $744.4M. The 52-week trading range was $1.99 to $15.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.